Trial
NCT00183937
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Southern California
Collaborators
Millennium Pharmaceuticals, Inc.
Condition
Prostate Cancer
Intervention
PS 341
Why stopped
Sponsor stopped study early.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-15